| Dr Karen Zimmerman, MD | |
|
800 W Central Rd, Arlington Heights, IL 60005-2349 | |
| (847) 618-5075 | |
| (847) 618-3259 |
| Full Name | Dr Karen Zimmerman |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 800 W Central Rd, Arlington Heights, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457517054 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036126325 (Illinois) | Secondary |
| 208M00000X | Hospitalist | 036126325 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Community Hospital 1 | Arlington heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Community Health Services Inc | 3375737331 | 275 |
News Archive
Most biologists and medical professionals would agree that skiing and running can delay aging. This is essentially because of the direct positive impact on the body due to good exercise and physical fitness.
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.
The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly today by the College of American Pathologists and the American Society of Clinical Oncology, reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.
› Verified 1 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
Most biologists and medical professionals would agree that skiing and running can delay aging. This is essentially because of the direct positive impact on the body due to good exercise and physical fitness.
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.
The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly today by the College of American Pathologists and the American Society of Clinical Oncology, reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.
› Verified 1 days ago
| Entity Name | Northwest Community Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134433154 PECOS PAC ID: 3375737331 Enrollment ID: O20101103000837 |
News Archive
Most biologists and medical professionals would agree that skiing and running can delay aging. This is essentially because of the direct positive impact on the body due to good exercise and physical fitness.
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.
The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly today by the College of American Pathologists and the American Society of Clinical Oncology, reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Karen Zimmerman, MD 800 W Central Rd, Arlington Heights, IL 60005-2349 Ph: (847) 618-5075 | Dr Karen Zimmerman, MD 800 W Central Rd, Arlington Heights, IL 60005-2349 Ph: (847) 618-5075 |
News Archive
Most biologists and medical professionals would agree that skiing and running can delay aging. This is essentially because of the direct positive impact on the body due to good exercise and physical fitness.
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.
The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly today by the College of American Pathologists and the American Society of Clinical Oncology, reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.
› Verified 1 days ago
Dr. Doron Galili, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 847-227-8987 | |
Rushabh Shah, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 877-635-9229 Fax: 847-618-3259 | |
Ahtesham Hyder, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 877-635-9229 Fax: 847-618-3259 | |
Ayham Alagha, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 877-635-9229 Fax: 847-618-3259 |